Biotechnology
HistoIndex Secures SGD9 Million Investment to Drive Next Phase of Expansion
SINGAPORE, May 2, 2025 /PRNewswire/ -- HistoIndex, known for its groundbreaking biophotonic Second Harmonic Generation (SHG) technology and a pioneering leader in Artificial Intelligence (AI) digital pathology for the management of fibrotic diseases, has announced the close of a S$9 million inves...
2025-05-02 10:00
2807
A Pivotal Phase II/III Clinical Study of Anti-HER2 Bispecific Antibody KN026 Have Met the Primary Endpoint of PFS at Interim Analysis
SUZHOU, China, May 1, 2025 /PRNewswire/ -- Alphamab Oncology (stock code: 9966.HK) and CSPC Pharmaceutical Group Co., Ltd. ("CSPC") (Stock Code: 1093.HK) jointly announced that a phase II/III clinical trial of anti-HER2 bispecific antibody KN026 (Study ID: KN026-001) in combination with chemother...
2025-05-01 09:49
2917
S&E bio Receives Korea's First Approval for Exosome-Based Therapy Clinical Trial
SEOUL, South Korea, May 1, 2025 /PRNewswire/ -- S&E bio Co., Ltd.
2025-05-01 08:00
2652
JediCare Medical has announced successful completion of its first-in-human feasibility study of the world's first-of-its-kind Pulmonary Nodule Percutaneous Sphere Resection
SHANGHAI, April 30, 2025 /PRNewswire/ -- JediCare Medical Technology Co., Ltd. a Shanghai, China based company ("the Company"), jointly with West China Hospital ofSichuan University, recently announced the successful completion of first-in-human ("FIH") feasibility study of its innovative, proprie...
2025-04-30 21:00
1928
ZEISS unveils AI-powered Research Data Platform; collaboration with Boehringer Ingelheim champions the future of personalized eye care
Showcasing the future of ophthalmic research at ARVO 2025: * ZEISS Research Data Platform launch - a cloud-based, AI-driven technology solution designed to accelerate discoveries, integrating research and clinical data, and simplifying research workflows. * ZEISS's collaboration with Boehring...
2025-04-30 21:00
2267
Mabwell Releases 6 Study Results of Innovative Drugs and Platforms at the 2025 AACR Annual Meeting
SHANGHAI, April 30, 2025 /PRNewswire/ -- Mabwell (688062.SH), an innovation-driven biopharmaceutical company with entire industry chain, presented 6 study results of innovative drugs and platforms in poster format at the American Association for Cancer Research (AACR) annual meeting, held from Ap...
2025-04-30 20:00
2226
Genocury Biotech Annouces Groundbreaking Advance in Relapsed/Refractory DLBCL Through Pioneering In Vivo CD19 CAR-T Therapy
Genocury launched the in vivo CD19 CAR-T therapy to reach the clinical stage, demonstrating exceptional safety, efficiency and durability. Results are attained without requiring lymphodepletion. SHENZHEN, China, April 30, 2025 /PRNewswire/ -- Genocury Biotech today revealed groundbreaking clinic...
2025-04-30 15:11
1892
Alphamab Oncology Presented Preclinical Data on Two Novel Bispecific ADCs at the 2025 AACR Annual Meeting
SUZHOU, China, April 30, 2025 /PRNewswire/ -- Alphamab Oncology (stock code: 9966.HK) announced that the preclinical data on two novel bispecific antibody-drug conjugates (ADCs) JSKN021 and JSKN022 were presented as posters at the 2025 American Association for Cancer Research (AACR) Annual Meetin...
2025-04-30 10:35
2600
Innovent Announces First Patient Dosed in Phase 1 Study of IBI3020, Global First-in-class Dual Payload CEACAM5 ADC, in Patients with Advanced Malignancies
SAN FRANCISCO and SUZHOU, China, April 30, 2025 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures, and commercializes high-quality medicines for the treatment of oncology, autoimmune, metabolic, ophthalmology a...
2025-04-30 08:00
2747
Everest Medicines Announces New Drug Application Approval of VELSIPITY® for Adults with Moderately to Severely Active Ulcerative Colitis in Hong Kong
SHANGHAI, April 30, 2025 /PRNewswire/ -- Everest Medicines (HKEX 1952.HK, "Everest", or the "Company"), a biopharmaceutical company focused on the discovery, clinical development, manufacturing, and commercialization of innovative therapeutics, today announced that the Department of Health of the...
2025-04-30 07:45
2500
Henlius Enters into License Agreement with Sandoz for Proposed Ipilimumab Biosimilar
* Partnership covers North America, Europe, Japan, and Australia to accelerate global access of HLX13 in immuno-oncology combinations * Henlius to receive $31 million upfront, and up to $270 million in milestones SHANGHAI, April 29, 2025 /PRNewswire/ -- On April 29, 2025, Shanghai Henlius Biot...
2025-04-29 23:39
2971
Henlius Enters into License Agreement with Sandoz for Proposed Ipilimumab Biosimilar
* Partnership covers North America, Europe, Japan, and Australia to accelerate global access of HLX13 in immuno-oncology combinations * Henlius to receive $31 million upfront, and up to $270 million in milestones SHANGHAI, April 29, 2025 /PRNewswire/ -- On April 29, 2025, Shanghai Henlius Biot...
2025-04-29 23:38
2513
PHASE Scientific Earns Prestigious Recognition at 2025 ASCCP Scientific Meeting for Innovation in Urine-Based HPV Screening
SAN DIEGO, April 29, 2025 /PRNewswire/ -- PHASE Scientific (PHASE) proudly announced a major milestone this week with its inaugural participation and award-winning presentation at the 2025 American Society for Colposcopy and Cervical Pathology (ASCCP) Annual Scientific Meeting — one of the foremo...
2025-04-29 22:00
2362
Metabolon Launches Microbiome Research Solution Combining New Microbiome Panel, Metagenomics Sequencing, and Multiomics Bioinformatics Tools
The combination of metagenomics and metabolomics data, integrated within an intuitive bioinformatics platform, enables deeper microbiome insights than possible with either approach individually MORRISVILLE, N.C., April 29, 2025 /PRNewswire/ -- Metabolon, Inc., the global leader in providing met...
2025-04-29 21:00
1661
Driving Impact Through Responsibility: WuXi Biologics Releases 2024 Sustainability Report
* Contributing to United Nations Sustainable Development Goals * Enhancing transparency and effectiveness for corporate governance * Empowering employees and delivering positive impact to communities * Accelerating actions for tackling climate change and promoting environmental stewardship ...
2025-04-29 18:47
2301
Amorepacific Research Confirms Potential of Microalgal-Derived PDRNs in Skin Regeneration and Wound Healing
New findings suggest 'BluePDRN™' offers a sustainable, scalable alternative to traditional animal-derived PDRNs SEOUL, South Korea, April 29, 2025 /PRNewswire/ -- Amorepacific revealed research findings confirming the skin-regenerative effects of polydeoxyribonucleotides (PDRNs) extracted from ...
2025-04-29 09:00
2645
Juncell Therapeutics Announces Data on Feeder-free IL-2-Independent TIL Manufacturing Process at ASGCT Annual Meeting 2025
SHANGHAI, April 28, 2025 /PRNewswire/ -- Shanghai Juncell Therapeutics Co., Ltd. (Juncell Therapeutics), a clinical-stage biotech specializing in developing innovative IL-2-independent Tumor-Infiltrating Lymphocyte (TIL) therapies for cancer, today announced it will present preclinical data on a ...
2025-04-29 08:08
1710
AI Evolution and Life Sciences: Embracing New Frontiers at Dalton Venture CEO Summit 2025
HONG KONG, April 29, 2025 /PRNewswire/ -- Dalton Venture CEO Summit 2025 , jointly hosted by Dalton Venture and Hong Kong Science and Technology Parks Corporation (HKSTP), successfully concluded at Hong Kong Science Park. The summit brought together over 100 distinguished guests, including gover...
2025-04-29 07:00
2788
KOLON TISSUEGENE HIGHLIGHTS LONG-TERM SAFETY DATA AND POTENTIAL U.S. FDA PATHWAY FOR TG-C AT OARSI WORLD CONGRESS
* THE WORLD'S MOST PRESTIGIOUS OSTEOARTHRITIS SOCIETY (OARSI) HELD FOR THE FIRST TIME IN KOREA * LONG-TERM SAFETY DATA FROM OVER 1 5 YEARS SUPPORT THE SAFETY PROFILE OF TG-C, WITH PRELIMINARY SIGNS OF POTENTIAL EFFICACY BENEFITS ROCKVILLE, Md., April 28, 2025 /PRNewswire/ -- Kolon TissueGen...
2025-04-28 21:16
2906
Complete Genomics, Velsera partner to integrate sequencing and analysis platforms
CHICAGO, April 28, 2025 /PRNewswire/ -- Complete Genomics,
2025-04-28 21:00
2173
Week's Top Stories
Most Reposted
iQIYI LAND Yangzhou to Open on February 8, Marking New Chapter in China's Immersive Entertainment Scene
[Picked up by 274 media titles]
2026-01-01 10:00
ACEN completes transition to 100% renewable energy
[Picked up by 273 media titles]
2025-12-29 18:53Vietnam's Newest EDM Destination, APLUS SAIGON, Debuts With Star-Studded Soft Opening Weekends Featuring Dombresky and Argy
[Picked up by 273 media titles]
2025-12-30 20:12
CYFIRMA's 2025 Impact Recap Showcases DeCYFIR, Preemptive External Threat Landscape Management Platform, Delivering Measurable Global Defense Against Emerging Threats
[Picked up by 263 media titles]
2025-12-29 09:00
ChinaAMC launches Depository Receipts of two Chinese flagship ETFs in Thai exchange
[Picked up by 260 media titles]
2025-12-29 14:27Most Read
POGMENT Biomimic Collagen Reacquired Recognition, Founder Appointed as Industrial Mentor for Master's Students at East China Normal University, Awarded 2025 Innovation Leadership Award
2025-12-31 17:21
5229
